CollPlant Biotechnologies (CLGN) Non-Current Assets (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Non-Current Assets came in at $4.0 million in Q4 2025, down 99.93% YoY from $5.5 billion in Q4 2024, and down 16.1% on a QoQ basis from $4.8 million in Q2 2025.
CollPlant Biotechnologies (CLGN) Non-Current Assets (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 9 years of Non-Current Assets data on file, last reported at $4.0 million in Q4 2025.
- Quarterly Non-Current Assets fell 99.93% year-over-year to $4.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.0 million (down 99.93% YoY) and the FY2025 annual result came in at $4.0 million, down 99.93% from the prior year.
- Non-Current Assets retreated to $4.0 million in Q4 2025, from $4.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $6137.0 billion in Q4 2021 to a low of $4.0 million in Q4 2025.
- A 5-year average of $342.9 billion and a median of $6.5 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets surged 118818873.86% — and 2025, when it sank 99.93%.
- Tracing CLGN's Non-Current Assets over 5 years: stood at $6137.0 billion in 2021, then tumbled by 99.9% to $6.1 billion in 2022, then slumped by 99.9% to $6.1 million in 2023, then surged by 90496.33% to $5.5 billion in 2024, then slumped by 99.93% to $4.0 million in 2025.
- The last three Non-Current Assets figures came in at $4.0 million (Q4 2025), $4.8 million (Q2 2025), and $5.5 billion (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.04 Mn |
| Jun 30, 2025 | 4.81 Mn |
| Dec 31, 2024 | 5.53 Bn |
| Sep 30, 2024 | 5.95 Bn |
| Jun 30, 2024 | 6.23 Mn |
| Mar 31, 2024 | 5.82 Bn |
| Dec 31, 2023 | 6.10 Mn |
| Sep 30, 2023 | 6.35 Bn |
| Jun 30, 2023 | 6.71 Mn |
| Mar 31, 2023 | 6.70 Mn |
| Dec 31, 2022 | 6.11 Bn |
| Sep 30, 2022 | 6.10 Mn |
| Jun 30, 2022 | 6.14 Mn |
| Mar 31, 2022 | 6.11 Mn |
| Dec 31, 2021 | 6,137.00 Bn |
| Sep 30, 2021 | 5.73 Mn |
| Jun 30, 2021 | 5.25 Mn |
| Mar 31, 2021 | 5.17 Bn |
| Dec 31, 2020 | 5.17 Mn |
| Sep 30, 2020 | 5.32 Mn |